Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 6/20 | 0.53 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.53 |
| ▸ | METAP2 | P50579 | 3/20 | 0.53 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.48 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.47 |
| ▸ | AXL | P30530 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30457395 | 1.00 | NOS1 (0.53) | NOS1DYRK1AMETAP2CSNK2A1CHEK1 | |
| SCHEMBL1601314 | 0.83 | NOS1 (0.53) | NOS1DYRK1AMETAP2CSNK2A1CHEK1 | |
| SCHEMBL29406909 | 0.83 | NOS1 (0.53) | NOS1DYRK1AMETAP2CSNK2A1CHEK1 | |
| Hydrochloric Acid SCHEMBL30667970 | 0.81 | NOS1 (0.52) | NOS1DYRK1AMETAP2CSNK2A1CHEK1 | |
| SCHEMBL8285951 | 0.74 | CHEK1 (0.47) | NOS1DYRK1AMETAP2CSNK2A1CHEK1 | |
| SCHEMBL14675972 | 0.74 | CHEK1 (0.57) | NOS1DYRK1AMETAP2CSNK2A1CHEK1 | |
| SCHEMBL29366050 | 0.74 | NOS1 (0.53) | NOS1DYRK1AMETAP2CSNK2A1CHEK1 | |
| SCHEMBL5066090 | 0.74 | NOS1 (0.53) | NOS1DYRK1AMETAP2CSNK2A1CHEK1 | |
| SCHEMBL29425049 | 0.74 | CHEK1 (0.47) | NOS1DYRK1AMETAP2CSNK2A1CHEK1 | |
| SCHEMBL29490938 | 0.74 | CHEK1 (0.57) | NOS1DYRK1AMETAP2CSNK2A1CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4736854-A2 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | Bristol-Myers Squibb Company (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4482583-B1 | ZWITTERIONIC ANTIBACTERIAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2026-04-01 | — | — | EP | disclosed |
| EP-4514473-B1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | BRISTOL MYERS SQUIBB CO (US) | 2026-02-18 | — | — | EP | disclosed |
| US-12497359-B2 | Acrylamide derivatives | NRG THERAPEUTICS LTD (GB) | 2025-12-16 | — | — | US | disclosed |
| US-20250320183-A1 | Modulators of BCL6 as Ligand Directed Degraders | CELGENE CORPORATION (US) | 2025-10-16 | — | — | US | disclosed |
| US-12404239-B2 | Modulators of BCL6 as ligand directed degraders | CELGENE CORPORATION (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250179066-A1 | ZWITTERIONIC ANTIBACTERIAL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-06-05 | — | — | US | disclosed |
| WO-2025111251-A1 | COMPOUNDS THAT INHIBIT POLO-LIKE KINASE 4 | EXELIXIS, INC. (US) | 2025-05-30 | — | — | WO | disclosed |
| WO-2025096706-A1 | MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-05-08 | — | — | WO | disclosed |
| WO-2025096771-A1 | MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-05-08 | — | — | WO | disclosed |
| US-9951064-B2 | Azaindazole compounds as inhibitors of T790M containing EGFR mutants | GENENTECH, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| WO-2017004500-A9 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | WO | disclosed |
| US-20170008877-A1 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-01-12 | — | — | US | disclosed |
| WO-2017004500-A1 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-01-05 | — | — | WO | disclosed |
| US-20160257682-A1 | AZAINDAZOLE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | GENENTECH, INC. (US) | 2016-09-08 | — | — | US | disclosed |
| US-20160257682-A1 | AZAINDAZOLE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | GENENTECH, INC. (US) | 2016-09-08 | — | — | US | disclosed |
| US-20160257682-A1 | AZAINDAZOLE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | GENENTECH, INC. (US) | 2016-09-08 | — | — | US | disclosed |
| EP-3052494-A1 | AZAINDAZOLE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | Genentech, Inc. (US) | 2016-08-10 | — | — | EP | disclosed |
| WO-2014210354-A1 | AZAINDAZOLE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | GENENTECH, INC. (US) | 2014-12-31 | — | — | WO | disclosed |
| WO-2014210354-A1 | AZAINDAZOLE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | GENENTECH, INC. (US) | 2014-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179066-A1 | ZWITTERIONIC ANTIBACTERIAL COMPOUNDS | MRPL21, WIZ, CFTR | NOS1 2481/4885DYRK1A 1097/4885METAP2 3653/4885 |
| US-12404239-B2 | Modulators of BCL6 as ligand directed degraders | BCL6, BCL6B, BCL3 | NOS1 4614/4885DYRK1A 1618/4885METAP2 2855/4885 |
| US-20250320183-A1 | Modulators of BCL6 as Ligand Directed Degraders | BCL6, BCL6B, BCL3 | NOS1 4614/4885DYRK1A 1618/4885METAP2 2855/4885 |
| US-12497359-B2 | Acrylamide derivatives | ACR, GSTA2, GSTA1 | NOS1 1571/4885DYRK1A 4314/4885METAP2 3914/4885 |
| US-20170008877-A1 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | LSS, LPXN, CYP1B1 | NOS1 2222/4885DYRK1A 4212/4885METAP2 4498/4885 |
| US-20160257682-A1 | AZAINDAZOLE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | EGFR, ERBB2, ERBB3 | NOS1 4305/4885DYRK1A 580/4885METAP2 3590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.